BBNX Stock Analysis: Buy, Sell, or Hold?
BBNX - Beta Bionics, Inc. Common Stock
$12.83
-1.44 (-10.09%)
▼
5d:
-19.05%
30d:
-23.17%
90d:
+25.78%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When BBNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BBNX is down 19.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BBNX is down 19.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BBNX is currently trading at $12.83, which is considered oversold relative to its 30-day fair value range of $14.89 to $17.31.
Technical Outlook: Technically, BBNX is in a strong uptrend. The price is currently testing key support at $12.79. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.08 (+56.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BBNX is in a strong uptrend. The price is currently testing key support at $12.79. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.08 (+56.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.89 -
$17.31
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.1%)
- BULLISH: Trading 56.5% below Wall St target ($20.08)
- WARNING: Recommendation downgraded due to -19.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$14.89 -
$17.31
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$12.79
Resistance Level
$18.20
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.54
Wall Street Target
$20.08
(+56.5%)
Revenue Growth (YoY)
56.6%
Profit Margin
-60.3%
Share & Embed Analysis
Last updated: August 03, 2026 2:52 AM ET
Data refreshes hourly during market hours. Next update: 3:52 AM
Data refreshes hourly during market hours. Next update: 3:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBNX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Hopman
SELL
353 shares
2026-03-04
Mark Hopman
SELL
834 shares
2026-03-02
Mike Mensinger
SELL
1064 shares
2026-03-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$64 | 55 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$384 | 51 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 52 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 57 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$236 | 51 HOLD |
